Reich K, Gordon KB, Strober BE, et al. - In patients with moderate-to-severe psoriasis, guselkumab, a human monoclonal antibody that inhibits interleukin-23 by targeting the p19 subunit, maintains excellent levels of clinical response and improvement in patient-reported outcomes for up to 5 years.

• At baseline, 1,829 patients were randomly assigned to receive guselkumab 100 mg every 8 weeks, a placebo, or adalimumab.

• The proportions of patients in the guselkumab group who achieved clinical responses at week 252 in VOYAGE 1 and VOYAGE 2 were 84·1% and 82·0%, respectively [≥ 90% improvement in Psoriasis Area and Severity Index (PASI)]; 82·4% and 85·0% [Investigator’s Global Assessment (IGA) 0 or 1]; 52·7% and 53·0% (100% improvement in PASI) and 54·7% and 55·5% (IGA 0).

• The following HRQoL endpoints were met: 72·7% and 71·1% of patients (Dermatology Life Quality Index 0 or 1: no effect on patient’s life); 42·4% and 42·0% [Psoriasis Symptoms and Signs Diary (PSSD) symptom score = 0] and 33·0% and 31·0% (PSSD sign score = 0).

• As measured in VOYAGE 2 only, about 45% of patients reached ≥ 5-point reduction in Short Form-36 physical and mental component scores, and 80% stated no anxiety or depression (Hospital Anxiety and Depression Scale scores < 8).

• Adalimumab crossovers yielded similar results.

• Such results were sustained from week 52 in VOYAGE 1 and week 100 in VOYAGE 2.

• There were no new safety signals discovered.